Full text is available at the source.
Abstract
Less than 1% of transfected oligonucleotide-based gene therapeutics release into the cytosol, limiting their effectiveness.
- The efficacy of oligonucleotide-based gene therapeutics (OGTs) in clinical and experimental settings is often lower than anticipated.
- Only about 2% of tested small interfering RNAs (siRNAs) achieve the desired 70% target gene knockdown.
- Clinically approved OGTs tend to be effective primarily for genetic disorders that lack alternative treatments, with minimal therapeutic impact.
- Most approved OGTs and those in trials are antisense oligonucleotides (ASOs), while siRNAs have shown greater potency in cell culture studies.
- The delayed commercialization of siRNAs may be linked to off-target effects and the ongoing development of their design strategies.
Simplified